Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity. News about Structure Therapeutics often centers on progress in its GPCR-targeted pipeline, including clinical trial updates, preclinical data presentations, and capital markets activities related to its development programs.
Investors and observers following GPCR news can expect regular updates on aleniglipron (GSBR-1290), the company’s investigational once-daily oral small molecule GLP-1 receptor agonist. Press releases have covered topline Phase 2b and exploratory study results in people living with obesity or overweight with weight-related comorbidities, details of the ACCESS and ACCESS II clinical programs, body composition and maintenance switching studies, and plans for potential Phase 3 development.
Another frequent news theme is the company’s amylin receptor agonist portfolio, including ACCG-2671 and ACCG-3535. Structure Therapeutics has announced initiation of a first-in-human Phase 1 clinical study of ACCG-2671 for obesity, as well as late-breaking poster presentations showing preclinical data on weight loss and combination effects with GLP-1 receptor agonists. Updates also include disclosures about its broader oral metabolic franchise, such as GIPR, GCGR and APJR programs, and the LPA1R program for idiopathic pulmonary fibrosis.
In addition, GPCR news items include quarterly financial results, business updates, and information on public offerings of American Depositary Shares and pre-funded warrants conducted under an automatic shelf registration statement on Form S-3. Coverage may also highlight participation in healthcare investor conferences and outcomes of annual shareholder meetings. Readers interested in Structure Therapeutics news can use this page to track clinical milestones, financing transactions, and other corporate developments disclosed through press releases and SEC-related announcements.
Summary not available.
Summary not available.
Summary not available.
Structure Therapeutics Inc. (NASDAQ: GPCR) reported its financial results for Q4 2022 and the full year ended December 31, 2022. The company completed its upsized IPO, raising approximately $185.3 million, with net proceeds of around $166.7 million. This funding bolsters its efforts to develop GSBR-1290, an oral GLP-1 agonist for type 2 diabetes and obesity. The Phase 1b study is now completed, and the firm anticipates topline data from the upcoming Phase 1b and Phase 2a studies in the second half of 2023. The net loss for 2022 was $51.3 million, a significant increase from $38.0 million in 2021, primarily due to heightened R&D expenses.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully closed its upsized initial public offering (IPO) of 12,351,000 American depositary shares (ADSs) at a price of $15.00 per ADS, generating approximately $185.3 million before expenses. This offering included the full exercise of underwriters' options to purchase an additional 1,611,000 ADSs. The shares commenced trading on Nasdaq on February 3, 2023. Jefferies, SVB Securities, Guggenheim Securities, and BMO Capital Markets served as joint book-running managers for the offering. Structure Therapeutics focuses on developing novel oral small molecule therapeutics for metabolic and pulmonary diseases targeting the GPCR family.
Structure Therapeutics Inc. (NASDAQ: GPCR), backed by Qiming Venture Partners, successfully debuted on Nasdaq on February 3, 2023. Issued at $15.00 per ADS, it opened at $25.00, marking a 66.67% increase and a market cap of $915 million. Qiming Venture Partners has been an early investor since 2019. Structure Therapeutics focuses on converting biologics into orally available small molecules, targeting G-protein-coupled receptors. Their pipeline includes GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary conditions, with significant studies completed in September 2022.
Structure Therapeutics Inc. (NASDAQ: GPCR) has successfully priced its upsized initial public offering (IPO) of 10,740,000 American depositary shares (ADSs) at $15.00 per ADS, anticipating gross proceeds of approximately $161.1 million. The offering includes a 30-day option for underwriters to purchase an additional 1,611,000 ADSs. Trading on the Nasdaq Global Market is set to begin on February 3, 2023, with completion expected by February 7, 2023. Structure Therapeutics focuses on developing novel oral therapeutics for metabolic and pulmonary diseases, leveraging a structure-based drug discovery platform.